Clinical Trials Logo

Clinical Trial Summary

The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in Canada. This study is about collecting existing data only; participants receive teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. No new information will be collected during this study. The study will be conducted using data from the Takeda OnePath Patient Support Program (PSP) or Takeda Global Pharmacovigilance.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05371028
Study type Observational
Source Takeda
Contact Takeda Contact
Phone +1-877-825-3327
Email medinfoUS@takeda.com
Status Recruiting
Phase
Start date September 23, 2023
Completion date July 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT01674478 - Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies Phase 2
Completed NCT05113082 - Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intestinal Failure That Underwent Transplantation in Brazil
Recruiting NCT05561647 - A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using GATTEX